Article

Malaysia Cervical Cancer 10-Year Plan

Published on 03.30

Ministry of Health Malaysia National Strategic Plan (I)

In-depth Interpretation of the Ten-Year Action Plan for the Elimination of Cervical Cancer (2021-2030)

The "Malaysia Action Plan for Cervical Cancer Elimination (2021-2030)" released by the Ministry of Health Malaysia is the country's core initiative in response to the World Health Organization's call to "eliminate cervical cancer within this century." This plan not only sets clear elimination goals but also establishes a three-pronged core system of "expanding HPV vaccination, strengthening cervical cancer screening, and improving the treatment of lesions and cancer." The plan aims to fully achieve the 90-70-90 target by 2030 (i.e., 90% HPV vaccination coverage, 70% screening coverage, and 90% treatment rate for precancerous lesions).

This article will comprehensively analyze the core content of this action plan, providing strategic references and planning suggestions tailored to local needs for Chinese pharmaceutical and medical device companies interested in the Malaysian market.

I. Current Status of Cervical Cancer Prevention and Control in Malaysia

Cervical cancer is the third most common malignant tumor among women in Malaysia. According to the latest population data, in 2024, Malaysia's female population is 16.2 million and the male population is 17.9 million. The age-standardized incidence rate of cervical cancer in the country from 2012-2016 was 6.2/100,000. In fact, since the beginning of the 21st century, Malaysia's prevention and control efforts have yielded results. The incidence rate of cervical cancer has decreased from 19.7/100,000 in 2003 to 8.3/100,000 in 2007, and further decreased to 5.6/100,000 in 2016, showing a significant decline. According to the World Health Organization (WHO) definition, the core threshold for cervical cancer elimination is an annual incidence rate of ≤4 cases per 100,000 women. Compared to this standard, there is still considerable room for improvement. However, "weak screening" has always been a key bottleneck restricting the progress of cervical cancer prevention and control in Malaysia.

1) Outdated and singular screening methods: Since 1969, Malaysia has used traditional Pap smear tests for cervical cancer screening in women. This method was the sole primary screening tool in the country until 2019.

2) Extremely low screening coverage: Due to resource limitations, Malaysia has never implemented a nationwide screening program. The average coverage rate for "opportunistic screening" through traditional cytology between 2015-2020 was only 25%.

3) Complex reasons for low coverage: These include insufficient public awareness of cervical cancer, fear of unpleasant examination experiences, conservative beliefs, scarcity of medical resources, and lack of social support.

To accelerate progress towards elimination, Malaysia has initiated two key adjustments: First, introducing HPV vaccination to build a strong primary prevention line. Second, upgrading screening methods, recognizing that "vaccines cannot replace screening." The country is gradually transitioning from traditional cytology to more accurate molecular testing (HPV testing). In August 2019, the Federal Territory of Kuala Lumpur, Putrajaya, Kedah, and Kelantan were the first to adopt HPV testing as the primary screening method.

Malaysia's current screening plan is clear: the target population coverage needs to reach over 70%. The first phase will cover women aged 30-49, while women outside this age range will still be offered cytological screening. The second phase will expand the age range to 50-65, with future plans to achieve full coverage of HPV testing services for all women nationwide.

Despite significant progress, Malaysia still faces many gaps and obstacles in reducing the incidence and mortality of cervical cancer and completely eliminating it as a public health threat. This action plan is designed to address these issues, guide the Ministry of Health, relevant agencies, and partners in improving implementation efficiency, accelerating the achievement of elimination goals, and ensuring that Malaysian women receive higher quality health protection.

II. Strategic Overview of the "Malaysia National Cervical Cancer Elimination Action Plan 2021-2030"

1. Strategic Goal 2030 (90-70-90)

1) Vaccination: Achieve 90% HPV vaccination coverage for 13-year-old girls;

2) Screening Coverage: Achieve 70% HPV screening coverage for women aged 30-65;

3) Lesion Treatment: 90% of precancerous lesions receive standardized treatment.

2. Four Core Promotion Directions

1) Create a favorable policy and social environment for the elimination of cervical cancer;

2) Collaborate with all partners dedicated to cervical cancer prevention and control to work together;

3) Explore innovative ideas and technologies to facilitate goal achievement;

4) Accelerate the elimination of cervical cancer as a "public health problem."

III. Five Priority Areas: Specific Strategies and Implementation Pathways

The core of the action plan is to precisely address key issues through "Five Priority Strategies + Eight Specific Strategies" to ensure orderly progress in all work.

Priority 1 — Strengthen Governance and Policy Support

Effective prevention and control work cannot be achieved without solid institutional guarantees. This priority strategy focuses on "evidence-based planning, regulatory supervision, and quality control," establishing a governance structure composed of Ministry of Health representatives, screening experts, and clinical healthcare professionals. This structure is responsible for overall coordination, guidance, and management of activities, ensuring seamless integration of the cervical cancer prevention and control plan with the national healthcare system.

Strategy 1: Implement and efficiently manage the cervical cancer elimination plan

Priority 2 — Enhance Service Accessibility and Engagement

Primary healthcare is the core leverage, enabling more women to conveniently access screening and vaccination services while stabilizing medical costs. This strategy focuses on two key actions: First, improving public health literacy through health education, empowering women with knowledge about cervical cancer prevention and control, and encouraging them to proactively choose screening and vaccination. Second, establishing a closed-loop system for "screening-diagnosis-follow-up services" to ensure that women receive timely diagnostic results and further treatment recommendations after screening.

Strategy 2: Strengthen primary prevention by improving health literacy

Priority 3 — Upgrade Service Delivery Capacity

Strategy 3: Scale up to achieve 90% HPV vaccination coverage for women

Strategy 4: Strategic actions to achieve 70% screening coverage and 90% precancerous lesion treatment rate

1) Screening: Phased promotion of full HPV testing coverage, providing special screening services for women infected with HIV/STIs; first increase coverage to 40% from 2021-2023, then increase by 10% every 2-3 years, reaching 70% by 2030.

2) Treatment: Ensure 90% of precancerous lesions receive timely and standardized treatment to prevent progression to cancer.

Strategy 5: Strategic action to achieve treatment and care for 90% of cervical cancer cases.

Cervical cancer poses a heavy burden in low- and middle-income countries (approximately 85% of cases occur in these countries, accounting for 12% of female cancers). Malaysia will focus on improving the diagnosis and treatment system for cervical cancer patients, ensuring that 90% of confirmed cases receive effective treatment and care.

Priority 4 — Deepen Inter-departmental Collaboration

Strategy 6: Strengthen inter-departmental alliances with stakeholders by establishing networks and smart partnerships.

Inter-departmental collaboration is crucial for integrating shared knowledge reserves, expertise, technical tools, and financial resources to support the achievement of elimination goals. Only by building a collaborative platform, bringing together key stakeholders, and leading coordinated actions can the efficient implementation of translation work be ensured. This platform can help all parties to systematically solve problems and promote the effective implementation of various strategies, policies, and plans. Therefore, building a strong unified leadership mechanism and an inclusive inter-departmental collaboration system, and guiding core partners to work towards the same goal is the practical optimization path.

Priority 5 — Strengthen Monitoring, Evaluation, and Research

Strategy 7: Improve monitoring systems to support monitoring and evaluation activities.

Building an efficient information management system is the cornerstone for carrying out project monitoring and evaluation and ensuring its effectiveness. From the ideal perspective of policy implementation, customer case record information should be promoted to be interconnected with regional, national public health databases, and cancer registries to efficiently collect, integrate, and analyze key indicator data. If the integrated construction of the above systems is not yet feasible, adopting sentinel surveillance for data collection and dynamic tracking monitoring can be used as a practical alternative implementation plan.

Establishing robust monitoring and surveillance systems at the national and state levels is crucial, not only to establish benchmarks but also to monitor the impact of the broad interventions and activities implemented as part of the cervical cancer elimination strategy. Monitoring and evaluation also help program managers identify gaps and take concrete actions to improve coverage, quality, and effectiveness.

Strategy 8: Exploring the impact of screening and treatment methods on improving patient outcomes through research

Research and innovation are crucial for reducing the burden of cancer, improving treatment efficacy, and enhancing the quality of life for cancer patients. Research leads to new prevention strategies, diagnostic methods, treatment discoveries, and novel care models. As knowledge and techniques in cervical cancer care are constantly evolving, existing and new treatment methods should be evaluated, and those that yield the best results should be adopted.

IV. Core Recommendations for Chinese Pharmaceutical and Medical Device Companies to Enter the Malaysian HPV-Related Product Market

1. Vaccine Products: Focus on core populations and vaccination convenience

1) Target the vaccination scenario for 13-year-old girls, developing or promoting vaccine formulations suitable for adolescents, such as low-dose, easy-to-administer products, to align with the policy goal of 90% vaccination coverage.

2) Address the uneven distribution of medical resources in Malaysia by optimizing vaccine storage and transportation conditions, introducing products that are stable in storage and have low transportation costs, suitable for use in primary healthcare facilities.

3) Strengthen clinical data support for vaccine safety and efficacy, with a focus on highlighting protection against high-risk HPV subtypes, to align with the core needs of cervical cancer prevention and control in the region.

2. Screening Products: Align with screening upgrade trends and lower the barrier to use

1) Focus on developing cervical cancer methylation detection products to replace traditional Pap smears, improving screening efficiency and cost-effectiveness, and aligning with Malaysia's policy direction of transitioning from cytological screening to molecular testing.

2) Develop products that are simple to operate, have short testing cycles, and provide easily interpretable results, suitable for use by primary healthcare professionals, while also reducing patient discomfort during examinations and increasing willingness to participate.

3) Control product costs and offer cost-effective screening kits (including sampling tools and testing reagents) that are suitable for Malaysia's healthcare budget and primary care procurement capabilities.

3. Treatment and Care Products.

1) Focus on the treatment of precancerous lesions, promoting minimally invasive surgical instruments and accompanying drugs that are less traumatic and allow for faster recovery, to match the target of 90% treatment rate for precancerous lesions.

2) Develop post-operative care and rehabilitation products for cervical cancer patients, such as anti-infective drugs and nursing consumables, to improve the local diagnosis and treatment service chain.

3) Product design must comply with Malaysian medical operating standards, be compatible with mainstream local diagnostic and treatment equipment, and reduce resistance to clinical application.

(This article is for policy interpretation and knowledge sharing in the medical industry only. The content is for reference only. Please cite the original source if you need to reprint.)